Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models

• Published in: Cancer immunology research Vol. 4; no. 1; p. 49
• Main Authors: Rhode, Peter R, Egan, Jack O, Xu, Wenxin, Hong, Hao, Webb, Gabriela M, Chen, Xiaoyue, Liu, Bai, Zhu, Xiaoyun, Wen, Jinghai, You, Lijing, Kong, Lin, Edwards, Ana C, Han, Kaiping, Shi, Sixiang, Alter, Sarah, Sacha, Jonah B, Jeng, Emily K, Cai, Weibo, Wong, Hing C
• Format: Journal Article
• Language: English
• Published: United States 01.01.2016
• Subjects: Adjuvants, Immunologic - pharmacokinetics; Adjuvants, Immunologic - therapeutic use; Adjuvants, Immunologic - toxicity; Animals; Antineoplastic Agents - pharmacokinetics; Antineoplastic Agents - therapeutic use; Antineoplastic Agents - toxicity; Cell Line, Tumor; Cell Proliferation; Cytokines - metabolism; Female; Humans; Immunotherapy; Interleukin-15 - pharmacokinetics; Interleukin-15 - therapeutic use; Interleukin-15 - toxicity; Killer Cells, Natural - drug effects; Killer Cells, Natural - physiology; Macaca fascicularis; Melanoma, Experimental - drug therapy; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasm Transplantation; Proteins - pharmacokinetics; Proteins - therapeutic use; Proteins - toxicity; Tissue Distribution; Tumor Burden - drug effects; Xenograft Model Antitumor Assays

IL15, a potent stimulant of CD8(+) T cells and natural killer (NK) cells, is a promising cancer immunotherapeutic. ALT-803 is a complex of an IL15 superagonist mutant and a dimeric IL15 receptor αSu/Fc fusion protein that was found to exhibit enhanced biologic activity in vivo, with a substantially...